Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma

Sunitha Kakarla, Kevin K.H. Chow, Melinda Mata, Donald R. Shaffer, Xiao Tong Song, Meng Fen Wu, Hao Liu, Lisa L. Wang, David R. Rowley, Klaus Pfizenmaier, Stephen Gottschalk

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Cancer-associated fibroblasts (CAFs), the principle component of the tumor-associated stroma, form a highly protumorigenic and immunosuppressive microenvironment that mediates therapeutic resistance. Co-targeting CAFs in addition to cancer cells may therefore augment the antitumor response. Fibroblast activation protein-α (FAP), a type 2 dipeptidyl peptidase, is expressed on CAFs in a majority of solid tumors making it an attractive immunotherapeutic target. To target FAP-positive CAFs in the tumor-associated stroma, we genetically modified T cells to express a FAP-specific chimeric antigen receptor (CAR). The resulting FAP-specific T cells recognized and killed FAP-positive target cells as determined by proinflammatory cytokine release and target cell lysis. In an established A549 lung cancer model, adoptive transfer of FAP-specific T cells significantly reduced FAP-positive stromal cells, with a concomitant decrease in tumor growth. Combining these FAP-specific T cells with T cells that targeted the EphA2 antigen on the A549 cancer cells themselves significantly enhanced overall antitumor activity and conferred a survival advantage compared to either alone. Our study underscores the value of co-targeting both CAFs and cancer cells to increase the benefits of T-cell immunotherapy for solid tumors.

Original languageEnglish (US)
Pages (from-to)1611-1620
Number of pages10
JournalMolecular Therapy
Volume21
Issue number8
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Fibroblasts
T-Lymphocytes
Neoplasms
Proteins
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
Antigen Receptors
Adoptive Transfer
Immunosuppressive Agents
Stromal Cells
Immunotherapy
Lung Neoplasms
Cancer-Associated Fibroblasts
Cytokines
Antigens
Survival
Growth

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Kakarla, S., Chow, K. K. H., Mata, M., Shaffer, D. R., Song, X. T., Wu, M. F., ... Gottschalk, S. (2013). Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Molecular Therapy, 21(8), 1611-1620. https://doi.org/10.1038/mt.2013.110

Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. / Kakarla, Sunitha; Chow, Kevin K.H.; Mata, Melinda; Shaffer, Donald R.; Song, Xiao Tong; Wu, Meng Fen; Liu, Hao; Wang, Lisa L.; Rowley, David R.; Pfizenmaier, Klaus; Gottschalk, Stephen.

In: Molecular Therapy, Vol. 21, No. 8, 01.01.2013, p. 1611-1620.

Research output: Contribution to journalArticle

Kakarla, S, Chow, KKH, Mata, M, Shaffer, DR, Song, XT, Wu, MF, Liu, H, Wang, LL, Rowley, DR, Pfizenmaier, K & Gottschalk, S 2013, 'Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma', Molecular Therapy, vol. 21, no. 8, pp. 1611-1620. https://doi.org/10.1038/mt.2013.110
Kakarla S, Chow KKH, Mata M, Shaffer DR, Song XT, Wu MF et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Molecular Therapy. 2013 Jan 1;21(8):1611-1620. https://doi.org/10.1038/mt.2013.110
Kakarla, Sunitha ; Chow, Kevin K.H. ; Mata, Melinda ; Shaffer, Donald R. ; Song, Xiao Tong ; Wu, Meng Fen ; Liu, Hao ; Wang, Lisa L. ; Rowley, David R. ; Pfizenmaier, Klaus ; Gottschalk, Stephen. / Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. In: Molecular Therapy. 2013 ; Vol. 21, No. 8. pp. 1611-1620.
@article{94223dff8d7543b8956308f98b10f513,
title = "Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma",
abstract = "Cancer-associated fibroblasts (CAFs), the principle component of the tumor-associated stroma, form a highly protumorigenic and immunosuppressive microenvironment that mediates therapeutic resistance. Co-targeting CAFs in addition to cancer cells may therefore augment the antitumor response. Fibroblast activation protein-α (FAP), a type 2 dipeptidyl peptidase, is expressed on CAFs in a majority of solid tumors making it an attractive immunotherapeutic target. To target FAP-positive CAFs in the tumor-associated stroma, we genetically modified T cells to express a FAP-specific chimeric antigen receptor (CAR). The resulting FAP-specific T cells recognized and killed FAP-positive target cells as determined by proinflammatory cytokine release and target cell lysis. In an established A549 lung cancer model, adoptive transfer of FAP-specific T cells significantly reduced FAP-positive stromal cells, with a concomitant decrease in tumor growth. Combining these FAP-specific T cells with T cells that targeted the EphA2 antigen on the A549 cancer cells themselves significantly enhanced overall antitumor activity and conferred a survival advantage compared to either alone. Our study underscores the value of co-targeting both CAFs and cancer cells to increase the benefits of T-cell immunotherapy for solid tumors.",
author = "Sunitha Kakarla and Chow, {Kevin K.H.} and Melinda Mata and Shaffer, {Donald R.} and Song, {Xiao Tong} and Wu, {Meng Fen} and Hao Liu and Wang, {Lisa L.} and Rowley, {David R.} and Klaus Pfizenmaier and Stephen Gottschalk",
year = "2013",
month = "1",
day = "1",
doi = "10.1038/mt.2013.110",
language = "English (US)",
volume = "21",
pages = "1611--1620",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma

AU - Kakarla, Sunitha

AU - Chow, Kevin K.H.

AU - Mata, Melinda

AU - Shaffer, Donald R.

AU - Song, Xiao Tong

AU - Wu, Meng Fen

AU - Liu, Hao

AU - Wang, Lisa L.

AU - Rowley, David R.

AU - Pfizenmaier, Klaus

AU - Gottschalk, Stephen

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Cancer-associated fibroblasts (CAFs), the principle component of the tumor-associated stroma, form a highly protumorigenic and immunosuppressive microenvironment that mediates therapeutic resistance. Co-targeting CAFs in addition to cancer cells may therefore augment the antitumor response. Fibroblast activation protein-α (FAP), a type 2 dipeptidyl peptidase, is expressed on CAFs in a majority of solid tumors making it an attractive immunotherapeutic target. To target FAP-positive CAFs in the tumor-associated stroma, we genetically modified T cells to express a FAP-specific chimeric antigen receptor (CAR). The resulting FAP-specific T cells recognized and killed FAP-positive target cells as determined by proinflammatory cytokine release and target cell lysis. In an established A549 lung cancer model, adoptive transfer of FAP-specific T cells significantly reduced FAP-positive stromal cells, with a concomitant decrease in tumor growth. Combining these FAP-specific T cells with T cells that targeted the EphA2 antigen on the A549 cancer cells themselves significantly enhanced overall antitumor activity and conferred a survival advantage compared to either alone. Our study underscores the value of co-targeting both CAFs and cancer cells to increase the benefits of T-cell immunotherapy for solid tumors.

AB - Cancer-associated fibroblasts (CAFs), the principle component of the tumor-associated stroma, form a highly protumorigenic and immunosuppressive microenvironment that mediates therapeutic resistance. Co-targeting CAFs in addition to cancer cells may therefore augment the antitumor response. Fibroblast activation protein-α (FAP), a type 2 dipeptidyl peptidase, is expressed on CAFs in a majority of solid tumors making it an attractive immunotherapeutic target. To target FAP-positive CAFs in the tumor-associated stroma, we genetically modified T cells to express a FAP-specific chimeric antigen receptor (CAR). The resulting FAP-specific T cells recognized and killed FAP-positive target cells as determined by proinflammatory cytokine release and target cell lysis. In an established A549 lung cancer model, adoptive transfer of FAP-specific T cells significantly reduced FAP-positive stromal cells, with a concomitant decrease in tumor growth. Combining these FAP-specific T cells with T cells that targeted the EphA2 antigen on the A549 cancer cells themselves significantly enhanced overall antitumor activity and conferred a survival advantage compared to either alone. Our study underscores the value of co-targeting both CAFs and cancer cells to increase the benefits of T-cell immunotherapy for solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=84881312673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881312673&partnerID=8YFLogxK

U2 - 10.1038/mt.2013.110

DO - 10.1038/mt.2013.110

M3 - Article

VL - 21

SP - 1611

EP - 1620

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 8

ER -